BioCentury
ARTICLE | Clinical News

Sesen reports Phase III data for bladder cancer candidate Vicinium

May 25, 2018 6:22 PM UTC

Sesen Bio Inc. (NASDAQ:SESN) (formerly Eleven Biotherapeutics Inc.) said Vicinium (VB4-845) led to a complete response rate of 42% at three months in 77 evaluable bladder cancer patients with carcinoma in situ (CIS) in the Phase III VISTA trial. Data were presented at the American Urological Association meeting in San Francisco.

The open-label, North American trial has enrolled 133 patients with high-grade non-muscle invasive bladder cancer (NMIBC) previously treated with bacillus Calmette-Guérin (BCG). Patients received twice-weekly Vicinium for six weeks, followed by once-weekly Vicinium for six weeks and then every other week for up to two years...

BCIQ Company Profiles

Sesen Bio Inc.